Skip to content

Cinnamon trial reports glucose decreases from baseline

Glucose markers declined from starting levels in the extract groups. The abstract does not report the direction or size of a direct comparison with placebo.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Both extract groups showed decreases in fasting plasma glucose and HbA1c from their starting levels. Treatment assignment also predicted changes in these markers in regression analyses. The abstract does not report the direction or size of a direct placebo comparison, so these results cannot establish added benefit over placebo or an improvement in health outcomes.

Keep in mind

The abstract provides no effect sizes, confidence intervals, or adverse-event results. Its conclusion describes safety favorably, but the supplied details do not allow an independent assessment of harms or a comparison between doses.

THE RESULT, WITH CONTEXT

What researchers found

Statistically significant decreases

Fasting plasma glucose and HbA1c

Over four months in both extract groups versus their own starting levels; the abstract supplies no numerical direct comparison with placebo.

Diabetes Metab Syndr, 2025 · Original source ↓

What the trial measured

Researchers focused on changes in glucose markers, while also examining cholesterol, insulin resistance, blood pressure, and body measurements. These measurements address metabolic responses; the abstract reports no results for diabetes complications.

What the analysis can tell us

Regression models identified extract treatment as a predictor of glucose changes. Without the model estimates or a clear numerical placebo comparison, readers cannot judge the magnitude or practical importance of that finding.

CHECK THE ORIGINAL

The original publication

Efficacy and Safety of Cinnamomum zeylanicum (Ceylon cinnamon) for diabetes mellitus: a randomized, double blind, placebo-controlled clinical trial.

Ranasinghe P, Galappatthy P, Constantine GR et al.
Diabetes Metab Syndr · 2025

PubMed ID
41412108
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.